MedChemComm p. 963 - 968 (2018)
Update date:2022-08-02
Topics:
Pippione, Agnese C.
Sainas, Stefano
Federico, Antonella
Lupino, Elisa
Piccinini, Marco
Kubbutat, Michael
Contreras, Jean-Marie
Morice, Christophe
Barge, Alessandro
Ducime, Alex
Boschi, Donatella
Al-Karadaghi, Salam
Lolli, Marco L.
NF-κB-inducing kinase (NIK), an oncogenic drug target that is associated with various cancers, is a central signalling component of the non-canonical pathway. A blind screening process, which established that amino pyrazole related scaffolds have an effect on IKKbeta, led to a hit-to-lead optimization process that identified the aminopyrazole 3a as a low μM selective NIK inhibitor. Compound 3a effectively inhibited the NIK-dependent activation of the NF-κB pathway in tumour cells, confirming its selective inhibitory profile.
View Morewebsite:http://www.simagchem.com
Contact:+86-592-2680277
Address:21/F Hualong Office Building,No.6 Hubin East Road, Xiamen,China
LIAOYANG TENGYUAN FOOD ADDITIVE FACTORY
Contact:+86-419-5807666
Address:Haodianzi village,Hanling Town,Liaoyang county
Engineering Research Center of Pesticide, Heilongjiang Province
Contact:+86-451-86609001
Address:No.74 of Xuefu Road, Nangang District,
Anhui Redstar Pharmaceutical Corp., Ltd
Contact:+86-563-5120837
Address:Jingxian Industrial Development Zone, Anhui , China
Contact:Tel: +86-25-58353800
Address:23 Lijing Road, Nanjing Hi-Tech Zone, Nanjing, Jiangsu, China, 210061
Doi:10.1021/ja01513a058
(1959)Doi:10.1016/j.poly.2004.06.014
(2004)Doi:10.1007/s11094-020-02172-4
(2020)Doi:10.1021/ja00395a071
(1981)Doi:10.1055/s-1980-29275
(1980)Doi:10.1002/ejoc.200400291
(2004)